Portola Pharma (PTLA) Tops Q3 EPS by 54c

Portola Pharma (NASDAQ: PTLA) reported Q3 EPS of ($1.08), $0.54 better than the analyst estimate of ($1.62). Revenue for the quarter came in at $14.2 million versus the consensus estimate of $7.1 million.

For earnings history and earnings-related data on Portola Pharma (PTLA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c